Covidien (NYSE:COV) said it won CE Mark approval in the European Union for home use of its Nellcor bedside SpO2 patient monitoring system.
Mansfield, Mass.-based Covidien’s PM100N device is designed to continuously monitor pulse rates and oxygen levels in a home-care setting, according to a press release. It features Covidien’s SatSeconds alarm management technology, which helps caregivers distinguish between serious and minor monitoring events.
Help employers find you! Check out all the jobs and post your resume.
